{"entity":{"id":"nct05934513","kind":"trial","name":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","aka":[],"tldr":"A phase 1/2 trial of GFH009 in peripheral T-cell lymphomas, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.","summary":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) is a phase 1/2 interventional study registered as NCT05934513 by Genfleet Therapeutics (Shanghai) Inc., with 95 participants planned, started 2023-09-06 and due to reach its primary completion in 2025-12-30. Interventions recorded: GFH009.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05934513","url":"https://clinicaltrials.gov/study/NCT05934513"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05934513","phase":"1/2","setting":"A Phase Ib/II, Multicentre, Open-label Study to Assess the Efficacy, Safety/ Tolerability and Pharmacokinetic of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","enrolled":95,"outcomes":[]},"route":"/trials/nct05934513/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}]}}